UK Markets close in 8 hrs 28 mins
  • FTSE 100

    6,333.84
    0.00 (0.00%)
     
  • FTSE 250

    19,582.35
    +75.39 (+0.39%)
     
  • AIM

    1,035.04
    +4.01 (+0.39%)
     
  • GBP/EUR

    1.1258
    +0.0006 (+0.05%)
     
  • GBP/USD

    1.3348
    +0.0026 (+0.1962%)
     
  • BTC-GBP

    13,766.90
    -18.75 (-0.14%)
     
  • CMC Crypto 200

    367.92
    +6.49 (+1.80%)
     
  • S&P 500

    3,577.59
    +20.05 (+0.56%)
     
  • DOW

    29,591.27
    +327.79 (+1.12%)
     
  • CRUDE OIL

    43.52
    +0.46 (+1.07%)
     
  • GOLD FUTURES

    1,826.90
    -10.90 (-0.59%)
     
  • NIKKEI 225

    26,165.59
    +638.22 (+2.50%)
     
  • HANG SENG

    26,536.99
    +50.79 (+0.19%)
     
  • DAX

    13,126.97
    -10.28 (-0.08%)
     
  • CAC 40

    5,492.15
    -3.74 (-0.07%)
     

LIVONGO ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of LVGO and Encourages Investors to Contact the Firm

·2-min read

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Livongo Health, Inc. (NASDAQ: LVGO) breached their fiduciary duties or violated the federal securities laws in connection with the company’s merger with Teladoc Health, Inc. (NYSE: TDOC).

Click here to learn more and participate in the action.

On August 5, 2020, Livongo announced that it had signed an agreement to be acquired by Teladoc for approximately $18.5 billion. Pursuant to the merger agreement, Livongo’s stockholders will receive 0.5920 shares of Teladoc common stock and $11.33 in cash for each share of Livongo common stock owned. The deal is scheduled to close in the fourth quarter of 2020.

Bragar Eagel & Squire is concerned that Livongo’s board of directors oversaw an unfair process and ultimately agreed to an inadequate deal price. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Livongo’s stockholders.

If you own shares of Livongo and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato or Alexandra Raymond by email at investigations@bespc.com or telephone at (646) 860-9157, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200806005767/en/

Contacts

Bragar Eagel & Squire, P.C.
Melissa Fortunato, Esq.
Alexandra Raymond, Esq.
investigations@bespc.com
www.bespc.com